ProfileGDS5678 / 1423711_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 76% 76% 76% 75% 77% 72% 75% 76% 77% 75% 77% 76% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0399976
GSM967853U87-EV human glioblastoma xenograft - Control 25.0863976
GSM967854U87-EV human glioblastoma xenograft - Control 35.1785976
GSM967855U87-EV human glioblastoma xenograft - Control 45.207476
GSM967856U87-EV human glioblastoma xenograft - Control 55.0233975
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1190377
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5482672
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9862875
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1444676
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.336477
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9503575
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.215277
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0764376
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.0677676